Search | Clinical Trials Finder

Conditions: Asthma
Interventions: tiotropium-bromide, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Year to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo, tiotropium + Olodaterol, Tiotropium, Olodaterol, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more

Conditions: Asthma
Interventions: tiotropium high dose, placebo, tiotropium low dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Stockton, California • Normal, Illinois • Baltimore, Maryland + 5 more

Conditions: Asthma
Interventions: Tiotropium low dose QD, Tiotropium high dose QD, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Columbia, Missouri • Cincinnati, Ohio • Oklahoma City, Oklahoma + 3 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Year to 40 Years
Enrollment: 11,296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Respimat, Tiotropium; Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 3,991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 57
States / cities: Birmingham, Alabama • Mobile, Alabama • Berkeley, California + 48 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg, Placebo (for Olodaterol (BI1744)l), Placebo (for Tiotropium); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 3
States / cities: Jasper, Alabama • Clearwater, Florida • Tampa, Florida

Conditions: Asthma
Interventions: tiotropium 5mcg/day, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Riverside, California + 16 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: placebo to tiotropium + olodaterol, tiotropium +olodaterol, tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: San Diego, California • Torrance, California • Hartford, Connecticut

Conditions: Asthma
Interventions: tiotropium bromide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Stiolto Respimat, Placebo Respimat; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 45 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Torrance, California

Conditions: Asthma
Interventions: Placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,071 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 21
States / cities: Huntington Beach, California • Mission Viejo, California • San Diego, California + 17 more

Conditions: Cystic Fibrosis
Interventions: tiotropium Respimat® inhaler, Placebo Respimat® inhaler; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Not listed
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 15
States / cities: Tuscon, Arizona • San Diego, California • Jacksonville, Florida + 10 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BI 1744 CL plus tiotropium bromide, Respimat® Inhaler; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 5
States / cities: Clearwater, Florida • Tampa, Florida • Philadelphia, Pennsylvania + 2 more

Conditions: Asthma
Interventions: tiotropium Respimat low dose, placebo Respimat, tiotropium Respimat high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Plymouth, Minnesota • Columbia, Missouri • Cincinnati, Ohio + 4 more

Conditions: Asthma
Interventions: placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,032 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 18
States / cities: Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol; Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 15
States / cities: Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium + olodaterol, tiotropium, olodaterol, Placebo, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more

Conditions: Asthma
Interventions: Placebo, Tiotropium low dose mcg, Tiotropium high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 10
States / cities: Rolling Hills Estates, California • Denver, Colorado • North Dartmouth, Massachusetts + 7 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium bromide + Olodaterol, Sp(t)iolto® Respimat®; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,371,146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy), LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 90
States / cities: Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 84 more

Conditions: Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 25
States / cities: Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more

Conditions: Asthma
Interventions: GP MDI 28.8 μg, GP MDI 14.4 μg, GP MDI 7.2 μg, Placebo MDI, Spiriva Respimat 2.5 μg; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 1,077 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 232
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 188 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo, Tiotropium, Olodaterol, Tiotropium + Olodaterol, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 8
States / cities: Torrance, California • Hartford, Connecticut • Livonia, Michigan + 5 more

Search by objective public record fields.

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Tiotropium / Respimat One Year Study in COPD.

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

Tiotropium Bromide in Cystic Fibrosis

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients